Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Update Il y a 4 ans
Reference: NCT02631733

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Inclusion criteria

  • Malignant Solid Neoplasm

Links